18.23USD+0.22%Mkt Cap: 1.34B USDP/E: —Last update: 2026-05-26
MoonLake Immunotherapeutics, a clinical-stage biotechnology company, focuses on developing therapies for inflammatory skin and joint diseases. It develops Sonelokimab, a novel tri-specific IL-17A and IL-17F inhibiting Na…
Industry Peers
Biotechnology110.61BUSDP/E 25.8
105.81BDKKP/E 20.4
66.47BUSDP/E 15.5
46.56BEURP/E 30.5
43.89BEURP/E 36.5
39.41BUSDP/E 74.0
32.84BUSD—
32.05BSEKP/E 47.4
Indicators:|
Key Statistics
Company
Market Cap1.34B USD
Enterprise Value1.08B USD
Revenue (TTM)—
Gross Profit—
Net Income (TTM)-227.32M USD
Revenue/Share—
Last Price18.23 USD
Fiscal Year EndDec 2025
MR QuarterMar 2026
Employees130
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-5.36
PEG—
EV/EBITDA-4.07
EV/Revenue—
P/S—
P/B5.24
EPS (TTM)-3.88
EPS (Forward)-3.45
52W Range
5.95022% of range62.75
52W High62.75 USD
52W Low5.950 USD
Profitability
Gross Margin0.00%
Oper. Margin0.00%
EBITDA Margin0.00%
Profit Margin0.00%
ROE-74.66%
ROA-53.56%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-196.01M USD
CapEx (TTM)35.00K USD
FCF Margin—
FCF Yield—
Net Debt-257.12M USD
Net Debt/EBITDA0.97
Balance Sheet
Debt/Equity0.25
Current Ratio8.60
Quick Ratio7.89
Book Value/Sh3.522 USD
Cash/Share4.962 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating1.9 (Buy)
Target (Mean)27.62 USD
Target Range6.000 USD – 46.00 USD
# Analysts13
Ownership
Shares Out.73.62M
Float39.86M
Insiders9.68%
Institutions87.75%
Short Interest
Short Ratio5.2d
Short % Float12.77%
Short % Out.8.68%
Shares Short6.32M
Short (prev mo.)7.76M
Technical
SMA 5017.40 (+4.8%)
SMA 20022.24 (-18.0%)
Beta—
S&P 52W Chg28.31%
Avg Vol (30d)880.77K
Avg Vol (10d)1.18M
Technical Indicators
RSI (14)—
MACD—
MACD Signal—
MACD Hist.—
BB Upper—
BB Middle—
BB Lower—
BB Width—
ATR (14)—
Vol Ratio (20d)—